Core Insights - AsymBio has officially commenced commercial production at its Shanghai Fengxian Commercial Manufacturing Base, enhancing its integrated biologics CDMO services and commitment to innovative therapies [1][4] Facility Overview - The Fengxian facility spans 130,000 square meters and serves as a strategic hub within AsymBio's global network, providing flexible and scalable support across all clinical phases [2] - The facility is designed to offer tailored CDMO solutions from early development through to commercial production [2] Advanced Manufacturing Capabilities - The Fengxian base is equipped to manufacture a wide range of next-generation biotherapeutics, including ADCs, dual-payload ADCs, RDCs, APCs, PDCs, AOCs, monoclonal, bispecific, and multispecific antibodies, as well as recombinant proteins [3] Leadership and Strategic Goals - CEO Rui Yang emphasized that the launch of the Fengxian Base is a strategic milestone for global expansion, enhancing production capacity and service capabilities while strengthening supply chain resilience [4] Quality and Sustainability Commitment - The Fengxian facility operates under a quality management system that meets global regulatory standards and employs advanced biomanufacturing technology for cost reduction and flexibility [4] - The site adheres to Asymchem's ESG strategy and EHS management principles [4] Business Focus - AsymBio specializes in biopharmaceutical CDMO services, leveraging advanced technology platforms and extensive project experience to provide one-stop solutions for global clients [5]